NCT02376452

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Phase II Study of 2-weekly Raltitrexed Plus Irinotecan Regimen (RAILIRI) Versus Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) as Second-line Treatment in Advanced Colorectal Cancer Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.

Conditions

• Colorectal Carcinoma

Interventions

Type	Name	Description
DRUG	Raltitrexed	2mg/m2 iv gtt, d1
DRUG	Irinotecan	180 mg/m2 iv gtt, d1
DRUG	5-fluorouracil	5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
DRUG	Leucovorin	400mg/m2 iv gtt,d1

Timeline

• Start date: 2014-09-01
• Primary completion: 2015-12-01
• Completion: 2016-12-01
• First posted: 2015-03-03
• Last updated: 2015-03-03

Locations

1 site across 1 country: China